Indicaciones de los inhibidores de PCSK9 en la práctica clínica. Recomendaciones de la Sociedad Española de Arteriosclerosis (SEA), 2019
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Ascaso Gimilio, Juan Francisco
- dc.contributor.author Civeira, Fernando
- dc.contributor.author Guijarro, Carlos
- dc.contributor.author López Miranda, José
- dc.contributor.author Masana, Luís
- dc.contributor.author Mostaza, José María
- dc.contributor.author Pedro-Botet, Juan Carlos
- dc.contributor.author Pintó Sala, Xavier
- dc.contributor.author Valdivielso, Pedro
- dc.date.accessioned 2019-11-26T07:52:22Z
- dc.date.available 2019-11-26T07:52:22Z
- dc.date.issued 2019
- dc.description.abstract A group of experts convened by the Spanish Society of Arteriosclerosis (SEA) has been in charge of updating the SEA document on the indications of PCSK9 inhibitors (PCSK9i) in clinical practice that was published in 2016. This update is justified by the fact that the data from clinical trials carried out on a large scale with PCSK9i have shown that in addition to their high potency to lower atherogenic cholesterol, they reduce the risk of atherosclerotic cardiovascular disease, both in patients with stable disease, and with recent disease, and with a high degree of security. This update provides the recommendations and level of evidence for the prescription of iPCSK9 in patients with homozygous and heterozygous familial hypercholesterolemia, with atherosclerotic cardiovascular disease, and in primary prevention in patients with very high cardiovascular risk. These recommendations have been established taking into account the concentration of LDL-C, the clinical situation of the patient, the additional risk factors and the cost-effectiveness of their use.
- dc.format.mimetype application/pdf
- dc.identifier.citation Ascaso JF, Civeira F, Guijarro C, López Miranda J, Masana L, Mostaza JM. Et al. Indicaciones de los inhibidores de PCSK9 en la práctica clínica. Recomendaciones de la Sociedad Española de Arteriosclerosis (SEA), 2019. Clin Investig Arterioscler. 2019 May - Jun;31(3):128-139. DOI 10.1016/j.arteri.2019.04.002
- dc.identifier.doi http://dx.doi.org/10.1016/j.arteri.2019.04.002
- dc.identifier.issn 0214-9168
- dc.identifier.uri http://hdl.handle.net/10230/42973
- dc.language.iso spa
- dc.language.iso eng
- dc.publisher Elsevier
- dc.rights 0214- 9168/ © 2019 Los Autores. Publicado por Elsevier España,S.L.U. en nombre de Sociedad Española de Arteriosclerosis. Este es un artículo Open Access bajo la licencia CCBY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/). https://doi.org/10.1016/j.arteri.2019.04.002
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/
- dc.subject.keyword Cardiovascular disease
- dc.subject.keyword Clinical indications
- dc.subject.keyword Colesterol
- dc.subject.keyword Consensus document
- dc.subject.keyword Documento de consenso
- dc.subject.keyword Enfermedad cardiovascular
- dc.subject.keyword Familial hypercholesterolemia
- dc.subject.keyword Hipercolesterolemia familiar
- dc.subject.keyword Indicaciones clínicas
- dc.subject.keyword Inhibidores de la proproteína convertasa subtilisina kexina 9
- dc.subject.keyword Lipoproteínas de baja densidad
- dc.subject.keyword Low density lipoprotein
- dc.subject.keyword Number needed to treat
- dc.subject.keyword Número necesario a tratar
- dc.subject.keyword Proprotein convertase subtilisin kexin 9 inhibitors
- dc.subject.keyword Tratamiento
- dc.subject.keyword Treatment
- dc.title Indicaciones de los inhibidores de PCSK9 en la práctica clínica. Recomendaciones de la Sociedad Española de Arteriosclerosis (SEA), 2019
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion